Langetermijncomplicaties na behandeling voor zaadbalkanker en hodgkinlymfoom
Open

Stand van zaken
19-11-2010
A.W. (Sandra) van den Belt-Dusebout, Berthe M.P. Aleman, Jourik A. Gietema, Ronald de Wit, Mars B. van ’t Veer, P.J. (Elly) Lugtenburg, A.D.G. (Stijn) Krol en Floor E. van Leeuwen

Long-term complications following treatment of testicular cancer and Hodgkin lymphoma

Conflict of interest: none declared. Financial support: the authors received a grant from the Lance Armstrong Foundation and KWF Kankerbestrijding.

  • Patients who were treated in the past with radiotherapy or chemotherapy for testicular cancer or Hodgkin lymphoma are at risk of new malignancies and cardiovascular disease on the long run.

  • Two patient groups who were diagnosed in various hospitals in the Netherlands as having testicular cancer and Hodgkin lymphoma in the period 1965-1995 have survived for a mean period of almost 20 years by now.

  • Both patient groups have higher risks of a new malignancy or cardiovascular disease following radiotherapy and/or chemotherapy than the general population or patients treated without or with less intensive radiotherapy or chemotherapy.

  • As recovery of Hodgkin lymphoma is only achieved by a more intensive treatment approach than the treatment approach for testicular cancer, the risks of a new malignancy or cardiovascular disease are considerably higher among survivors of Hodgkin lymphoma than among survivors of testicular cancer.

  • In both patient groups the long-term risks of new malignancies and cardiovascular disease are still raised in both patient groups up to 25 years after treatment.

  • Because of the relatively high risks of late treatment complications, recommendations for follow-up for survivors of testicular cancer and Hodgkin lymphoma are necessary.